89 results found.

Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent S Clinical Trial using soy isoflavones; laboratory biomarker analysis; survey administration

National Cancer Institute (NCI) - Recruiting 19 years to 79 years.
- A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma.
soy isoflavones; laboratory biomarker analysis; survey administration

Oral Cancer Clinical Trial using Fluorescence Spectroscopy

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Fluorescence and Reflectance Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions.
Fluorescence Spectroscopy

Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck Clinical Trial using CC-115

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
CC-115

Head and Neck Neoplasms Clinical Trial using methotrexate; afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy.
methotrexate; afatinib

Childhood Mixed Glioma, Untreated Childhood Anaplastic Astrocytom Clinical Trial using veliparib; temozolomide; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- A Phase I/II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG).
veliparib; temozolomide; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy; pharmacological study; laboratory biomarker analysis

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using tivantinib; cetuximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Trial of ARQ 197 (Tivantinib) /Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer.
tivantinib; cetuximab; laboratory biomarker analysis

Esophageal Cancer Clinical Trial using early oral feeding

Henan Cancer Hospital - Recruiting 18 years to 80 years.
- Early Oral Feeding Following Thoracolaparoscopic Oesophagectomy in Patients With Esophageal Cancer: a Randomized Clinical Trial.
early oral feeding

Leukemia, Myelogenous, Chronic Clinical Trial using Nilotinib

M.D. Anderson Cancer Center - Recruiting 16 years or older.
- Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib.
Nilotinib

Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, or Me Clinical Trial using Topical Dapsone 5% Gel; Moisturizer; oral antibiotics

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT.
Topical Dapsone 5% Gel; Moisturizer; oral antibiotics

Oncology, BRCA Mutated, High Grade Serous Ovarian Cancer, or BRCA Clinical Trial using Veliparib

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors.
Veliparib

Advanced Solid Tumors (Excluding Breast Cancer) Clinical Trial using TAS-102 tablets; TAS-102 oral solution

Taiho Pharma USA, Inc. - Recruiting 18 years or older.
- A Phase 1, Open-label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 Tablets Relative to an Oral Solution Containing Equivalent Amounts of FTD and TPI.
TAS-102 tablets; TAS-102 oral solution

Advanced Cancers Clinical Trial using Oxaliplatin; Capecitabine; Bevacizumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I Clinical Trial of Hepatic Arterial Infusion of Oxaliplatin, Oral Capecitabine, With or Without Systemic Bevacizumab for Patients With Advanced Cancer Metastatic to the Liver.
Oxaliplatin; Capecitabine; Bevacizumab

Healthy Clinical Trial using isoquercetin or quercetin

Dana-Farber Cancer Institute - Recruiting 18 years to 60 years.
- Pharmacokinetic and Pharmacodynamic Study of Oral Quercetin and Isoquercetin in Healthy Adults and Patients With Elevated Anti-phospholipid Antibodies.
isoquercetin or quercetin

Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Clinical Trial using TKI258

Novartis - Recruiting 18 years or older.
- A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer.
TKI258

Non-Small Cell Lung Cancer Clinical Trial using LDK378

Novartis - Recruiting 18 years or older.
- A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib na‹ve Adult Patients With ALK-activated Non-small Cell Lung Cancer.
LDK378

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using calcitriol; cisplatin; gemcitabine hydrochloride; pharmacological study

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of Oral Calcitriol With Fixed Dose of Cisplatin and Gemcitabine in Patients With Advanced Solid Tumors.
calcitriol; cisplatin; gemcitabine hydrochloride; pharmacological study

Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Clinical Trial using Oral rucaparib

Clovis Oncology, Inc. - Recruiting 18 years or older.
- A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2).
Oral rucaparib

Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors.
CB-839

Pain, Neoplasms, or Chronic Pain Clinical Trial using Cebranopadol

Grnenthal GmbH - Recruiting 18 years or older.
- An Open-label, Multi-site Trial to Describe the Safety and Tolerability of Oral Cebranopadol Administered for 26 Weeks in Subjects With Cancer-related Pain Who Have Completed Treatment in the KF6005/07 Trial..
Cebranopadol

Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Brea Clinical Trial using BMN 673

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations.
BMN 673

Microbiota, Lung Cancer, or Oral Cancer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 25 years to 80 years.
- The Effect of Smoking on Oral Microbiota.

Pain, Neoplasms, or Chronic Pain Clinical Trial using Cebranopadol; Morphine Prolonged Release

Grnenthal GmbH - Recruiting 18 years or older.
- Efficacy, Safety, and Tolerability of Oral Cebranopadol Versus Morphine Sulfate PR in Subjects With Chronic Moderate to Severe Pain Related to Cancer..
Cebranopadol; Morphine Prolonged Release

Squamous Cell Carcinoma of the Oral Cavity, or Squamous Cell Carc Clinical Trial using GC4419

Galera Therapeutics, Inc. - Recruiting 18 years or older.
- A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck..
GC4419

Quality of Life, or Breakthrough Cancer Pain Clinical Trial using Fentanyl

Galena Biopharma, Inc. - Recruiting 18 years or older.
- Rapid Evaluation of Lifestyle, Independence, and Elimination of Breakthrough Cancer Pain With Freedom From Oral Discomfort Through the Use of Abstralr (Fentanyl) Sublingual Tablets.
Fentanyl

Periodontal Disease, or Quality of Life Clinical Trial

University of Michigan - Recruiting N/A or older.
- Oral Health in Breast Cancer Survivors on Aromatase Inhibitors.

Head and Neck Cancer, Oral Cavity Cancer, or Oropharyngeal Cancer Clinical Trial using Valproic Acid

Instituto do Cancer do Estado de Sao Paulo - Recruiting N/A to 65 years.
- Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.
Valproic Acid

Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Clinical Trial using Rucaparib

Clovis Oncology, Inc. - Recruiting 18 years or older.
- A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid Tumor.
Rucaparib

Stage IV Gastric Cancer Clinical Trial using Paclitaxel

Daehwa Pharmaceutical Co., Ltd. - Recruiting 20 years or older.
- A Randomized, Open, Multicenter Phase 3 Study for Efficacy and Safety Assessment of DHP107 (Oral Paclitaxel) vs. Taxolr in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy With Fluoropyrimidine +/- Platinum.
Paclitaxel

Head and Neck Cancer Clinical Trial using Proflavine; Imaging; Widefield Multispectral Imaging Devices; High-Resolution Microendoscope (HRME)

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Wide-Field and High Resolution In Vivo Imaging of Oral Neoplasia Using Topical Fluorescent Dyes: A Feasibility Study.
Proflavine; Imaging; Widefield Multispectral Imaging Devices; High-Resolution Microendoscope (HRME)

Systemic Anaplastic Large-Cell Lymphoma, Neoplasms, Anaplastic Ly Clinical Trial using PF-02341066; Rifampin; Ketoconazole

Pfizer - Recruiting 18 years or older.
- Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of PF-02341066, A c-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer.
PF-02341066; Rifampin; Ketoconazole

Oral Mucositis Clinical Trial using Clonidine Lauriadr 50æg; Clonidine Lauriadr 100æg; Placebo Lauriadr

BioAlliance Pharma SA - Recruiting 18 years or older.
- A Phase II, Multi-center, Randomised, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Lauriadr 50 æg and 100 æg Mucoadhesive Buccal Tablet (MBT) Applied Once Daily to Those of Placebo in the Prevention and Treatment of Chemoradiation Therapy Induced Oral Mucositis in Patients With Head and Neck Cancer.
Clonidine Lauriadr 50æg; Clonidine Lauriadr 100æg; Placebo Lauriadr

Ovarian Cancer, or Breast Cancer Clinical Trial using BKM120 and Olaparib

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer.
BKM120 and Olaparib

Oral Contraceptive Clinical Trial using Oral Contraceptive: Ortho-Novumr 1/35; Oral Contraceptive: Ovconr 35; Oral Contraceptive: Microgestin Fer 1/20

University of Southern California - Recruiting 18 years to 35 years.
- The Effects of Dose and Formulation of Oral Contraceptives (OCs) on Breast-Cell Proliferation: Can the Chemopreventive Effects of OCs on Endometrial and Ovarian Cancer be Extended to Breast Cancer?.
Oral Contraceptive: Ortho-Novumr 1/35; Oral Contraceptive: Ovconr 35; Oral Contraceptive: Microgestin Fer 1/20

Head and Neck Cancer Clinical Trial using Flexible Fiber-based CO2 Laser, Quality of Life forms; electrocautery resection and quality of life forms

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Flexible Fiber-based CO2 Laser Versus Monopolar Cautery for Resection of Benign, Pre-malignant And Malignant Oral Cavity Lesions: A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery.
Flexible Fiber-based CO2 Laser, Quality of Life forms; electrocautery resection and quality of life forms

Anorexia, Cachexia, Malignant Neoplasm, or Oral Complications of Clinical Trial using bovine lactoferrin supplement; questionnaire administration; quality-of-life assessment; laboratory biomarker analysis

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Pilot Study of Bovine Lactoferrin in Cancer Patients Reporting Taste Disturbances While Receiving Chemotherapy.
bovine lactoferrin supplement; questionnaire administration; quality-of-life assessment; laboratory biomarker analysis

Melanoma, Breast Neoplasms, Lobular Carcinoma, Triple-negative Br Clinical Trial using LGK974

Novartis - Recruiting 18 years or older.
- A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands.
LGK974

Stage 0/1 Breast Cancer, Post Biopsy, or Pre-surgery Clinical Trial using IV/oral n-acetylcysteine

Thomas Jefferson University - Recruiting 18 years or older.
- Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer.
IV/oral n-acetylcysteine

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using afatinib; placebo; laboratory biomarker analysis

Eastern Cooperative Oncology Group - Recruiting 18 years or older.
- A Randomized, Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence.
afatinib; placebo; laboratory biomarker analysis

Safety, Tolerability, Pharmacokinetics, or Cancer Clinical Trial using Dexanabinol; Placebo

e-Therapeutics PLC - Recruiting 18 years to 45 years.
- Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects.
Dexanabinol; Placebo

Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, S Clinical Trial using H1299 Lysate Vaccine; Cyclophosphamide; Celecoxib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum.
H1299 Lysate Vaccine; Cyclophosphamide; Celecoxib

Squamous Cell Carcinoma of the Oral Cavity, or Squamous Cell Carc Clinical Trial using LI plus CIZ; Standard of Care (SOC); LI + SOC

CEL-SCI Corporation - Recruiting 18 years or older.
- Phase III Study of LI [Multikiner] Plus SOC (Surgery + Radiotherapy or Surgery + Concurrent Radiochemotherapy) in Subjects With Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate vs. SOC Only.
LI plus CIZ; Standard of Care (SOC); LI + SOC

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial using MLN8237 and Erlotinib

Fox Chase Cancer Center - Recruiting 18 years or older.
- A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, In Combination With Erlotinib In Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer.
MLN8237 and Erlotinib

Carcinoma, Squamous Cell, Head and Neck Neoplasms, or Oropharynge Clinical Trial using Assessment of Oral HPV Infection

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Monitoring of Oral HPV Infection in HPV-positive Oropharyngeal Squamous Cell Carcinoma During and After Chemoradiotherapy (CRT).
Assessment of Oral HPV Infection

Prostatic Neoplasms Clinical Trial using CFG920

Novartis - Recruiting 18 years or older.
- A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer.
CFG920

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using TLR8 agonist VTX-2337; cetuximab; laboratory biomarker analysis; pharmacogenomic studies

University of Washington - Recruiting 18 years or older.
- Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN).
TLR8 agonist VTX-2337; cetuximab; laboratory biomarker analysis; pharmacogenomic studies

Prostatic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Mela Clinical Trial using Interactive Voice Response (IVR) Reminders

Michigan State University - Recruiting 21 years or older.
- Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR.
Interactive Voice Response (IVR) Reminders

Hepatectomy, Elective Hepatectomy, or Malignant Tumors Clinical Trial using Oral immunonutrition; Placebo

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- Interest of Preoperative Immunonutrition in Liver Resection for Cancer.
Oral immunonutrition; Placebo

Neoplasms, Oral, or Mouth Neoplasms Clinical Trial using GSK1120212

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase II Window of Opportunity Trial With GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer.
GSK1120212

Mesolthelioma, Esophageal Cancer, or Lung Cancer Clinical Trial using Celecoxib; ISCOMATRIX (TM) Adjuvant; Autologous Tumor Cell Vaccine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Epigenetically-Modified Autologous Tumor Cell Vaccines With ISCOMATRIX(TM) Adjuvant and Oral Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas.
Celecoxib; ISCOMATRIX (TM) Adjuvant; Autologous Tumor Cell Vaccine

Non-small Cell Lung Cancer Clinical Trial using Dacomitinib

Pfizer - Recruiting 18 years or older.
- Phase 2 Open Label Trial Of Oral Intermittent Dacomitinib In Patients With Advanced NSCLC.
Dacomitinib

Non-Small Cell Lung Cancer Clinical Trial using LDK378; pemetrexed; docetaxel

Novartis - Recruiting 18 years or older.
- A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib.
LDK378; pemetrexed; docetaxel

Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III S Clinical Trial using cisplatin; docetaxel; cetuximab; laboratory biomarker analysis; quality-of-life assessment; intensity-modulated radiation therapy

Radiation Therapy Oncology Group - Recruiting 18 years or older.
- Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck.
cisplatin; docetaxel; cetuximab; laboratory biomarker analysis; quality-of-life assessment; intensity-modulated radiation therapy

Solid Tumors, or Non-small Cell Lung Cancer Clinical Trial using oral 5-azacitidine in combination with romidepsin

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- Phase I Trial of Oral 5-azacitidine With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer.
oral 5-azacitidine in combination with romidepsin

Myeloma Clinical Trial using Pomalidomide; Dexamethasone; Cyclophosphamide

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma.
Pomalidomide; Dexamethasone; Cyclophosphamide

Cancer Clinical Trial using GSK2118436 75 mg; Placebo

GlaxoSmithKline - Recruiting 18 years or older.
- A Two-Part Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors: An Open-label, Dose-escalating Safety Lead-in Study Followed by a Single-sequence, Placebo-controlled, Single-blind Study.
GSK2118436 75 mg; Placebo

Colorectal Cancer, Dysgeusia, or Oral Complications of Chemothera Clinical Trial using questionnaire administration; quality-of-life assessment; laboratory biomarker analysis; bovine lactoferrin

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Pilot Study of Bovine Lactoferrin in Patients With Colorectal Carcinoma Receiving Oxaliplatin-Based Chemotherapy and Self-Reported Taste Disturbances.
questionnaire administration; quality-of-life assessment; laboratory biomarker analysis; bovine lactoferrin

Carcinoma, Non-Small-Cell Lung Clinical Trial using BIBW 2992; Sirolimus (rapamycin)

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- A Phase Ib Open Label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Sirolimus in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib.
BIBW 2992; Sirolimus (rapamycin)

Oral Mucositis Clinical Trial using SGX942; Placebo

Soligenix - Recruiting 18 years or older.
- A Phase 2,Double-Blind, Randomized, Placebo-Controlled, Dose Escalating, Multicenter Study of SGX942 For the Attenuation of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck.
SGX942; Placebo

Bladder Cancer Clinical Trial using bacilli calmette-guerin (BCG); lenalidomide

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- Immune Modulation by Addition of Oral Lenalidomide to Intravesical BCG (Bacille Calmette-Guerrin) for Therapy of Non-muscle-invasive Transitional Cell Bladder Cancer.
bacilli calmette-guerin (BCG); lenalidomide

Recurrent Small Cell Lung Cancer Clinical Trial using linsitinib; topotecan hydrochloride; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC).
linsitinib; topotecan hydrochloride; laboratory biomarker analysis; pharmacological study

Oral Cancer, Oropharynx Cancer, or Hypopharynx Cancer Clinical Trial using IMRT 75 Gy; Conventional radiotherapy 70 Gy; concomitant cisplatin

Groupe Oncologie Radiotherapie Tete et Cou - Recruiting 18 years or older.
- Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma.
IMRT 75 Gy; Conventional radiotherapy 70 Gy; concomitant cisplatin

Gastric Cancer, or Peritoneal Carcinomatosis Clinical Trial using Intraperitoneal docetaxel

The University of Hong Kong - Recruiting 18 years or older.
- Feasibility Study of Intraperitoneal Docetaxel Combined With Intravenous Cisplatin and Oral TS-ONE for Gastric Cancer Patients With Peritoneal Carcinomatosis.
Intraperitoneal docetaxel

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using docetaxel; cisplatin; carboplatin; fluorouracil; bevacizumab

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
docetaxel; cisplatin; carboplatin; fluorouracil; bevacizumab

Castration Refractory Prostate Cancer, or CRPC Clinical Trial using VT-464 Dose Level 1: given orally twice daily in 28 day cycles; VT-464 Dose Level 2: given orally twice daily in 28 day cycles; VT-464 Dose Level 3: given orally twice daily in 28 day cycles

Viamet Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Chemotherapy-Na‹ve Patients With Castration-Refractory Prostate Cancer.
VT-464 Dose Level 1: given orally twice daily in 28 day cycles; VT-464 Dose Level 2: given orally twice daily in 28 day cycles; VT-464 Dose Level 3: given orally twice daily in 28 day cycles

Neuroblastoma Clinical Trial using adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH

Memorial Sloan-Kettering Cancer Center - Recruiting N/A to 21 years.
- Phase I/II Trial of a Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral á-glucan for High-Risk Neuroblastoma.
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH

Head and Neck Cancer, Long-term Effects Secondary to Cancer Thera Clinical Trial using Acupuncture

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer.
Acupuncture

Advanced Solid Tumours Clinical Trial using AZD0424

Cancer Research UK - Recruiting 18 years or older.
- A Cancer Research UK Phase I Study to Determine the Maximum Tolerated Dose of the Oral Src/Abl Inhibitor AZD0424, and to Identify Tolerable and Effective AZD0424 Combination Regimens for the Treatment of Advanced Solid Tumours.
AZD0424

Oral Mucositis Clinical Trial using Mouthrinse & herbal extract; Mouthrinse

Medical University of South Carolina - Recruiting 18 years to 89 years.
- Randomized Controlled Double-blinded Clinical Trial of an Herbal Mouthrinse for Radiotherapy Induced Mucositis in Cancer Patients.
Mouthrinse & herbal extract; Mouthrinse

Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucou Clinical Trial using fluorescence imaging; biopsy; examination; Comparison of surgical margins by COE vs. DVFE

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- The Role of Direct Visual Fluorescence in Oral Examination.
fluorescence imaging; biopsy; examination; Comparison of surgical margins by COE vs. DVFE

Brain and Central Nervous System Tumors Clinical Trial using olaparib; temozolomide; gene expression analysis; protein expression analysis; laboratory biomarker analysis; pharmacological study; diffusion-weighted magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; therapeutic conventional surgery

Cancer Research UK - Recruiting 18 years to 70 years.
- A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma.
olaparib; temozolomide; gene expression analysis; protein expression analysis; laboratory biomarker analysis; pharmacological study; diffusion-weighted magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; therapeutic conventional surgery

Oral Cancer Clinical Trial

Roswell Park Cancer Institute - Recruiting 21 years or older.
- Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression.

Pancreatic Cancer Clinical Trial using GVAX pancreatic cancer vaccine; cyclophosphamide

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Randomized Three-arm Neoadjuvant and Adjuvant Feasibility and Toxicity Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine Administered Either Alone or in Combination With Either a Single Intravenous Dose or Daily Metronomic Oral Doses of Cyclophosphamide for the Treatment of Patients With Surgically Resected Adenocarcinoma of the Pancreas.
GVAX pancreatic cancer vaccine; cyclophosphamide

Oral Tumors Clinical Trial using FastEEM4 System; Multispectral Digital Microscope

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Oral Tumor Margin Detection Using Optical Spectroscopy.
FastEEM4 System; Multispectral Digital Microscope

Locally Advanced Resectable Oral Cavity Squamous Cell Cancer Clinical Trial using docetaxel, cisplatin, 5 fluorouracil

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano - Recruiting 18 years or older.
- Phase II Study of Preoperative TPF Chemotherapy in Locally Advanced Resectable Oral Cavity Squamous Cell Cancer in Order to Improve the Rate of Pathological Complete Response.
docetaxel, cisplatin, 5 fluorouracil

Head and Neck Cancer Clinical Trial using Intra-arterial cisplatin; Intravenous cisplatin

Southern Illinois University - Recruiting 18 years or older.
- A Pilot/ Feasibility Study Comparing Response Rates of Intra-arterial and Intravenous Cisplatin Chemotherapy, Combined With Radiation, in Patients With Locally Advanced Carcinoma of the Oral Cavity and Oropharynx.
Intra-arterial cisplatin; Intravenous cisplatin

Primary Non-operated Squamous Cell Carcinoma of Oral Cavity, Prim Clinical Trial using video fluoroscopy; extra imaging; scoring acute toxicity; scoring of late toxicity; scoring quality of life (QOL)

University Hospital, Ghent - Recruiting 18 years or older.
- Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck: a Multicenter, Two-arm, Randomized Phase II Trial..
video fluoroscopy; extra imaging; scoring acute toxicity; scoring of late toxicity; scoring quality of life (QOL)

Recurrent and Second Primary Squamous Cell Carcinoma of the Oral Clinical Trial using [18F]FDG-PET-voxel intensity-based IMRT

University Hospital, Ghent - Recruiting 18 years or older.
- A Feasibility Study on Adaptive 18F-FDG-guided Radiotherapy for Recurrent and Second Primary Head and Neck Cancer in the Previously Irradiated Territory..
[18F]FDG-PET-voxel intensity-based IMRT

Metastatic Breast Cancer Clinical Trial using lapatinib plus oral vinorelbine

National Taiwan University Hospital - Recruiting 20 years or older.
- Phase I/II Study of Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer.
lapatinib plus oral vinorelbine

Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Clinical Trial using crizotinib; pharmacogenomic studies; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma.
crizotinib; pharmacogenomic studies; pharmacological study

Abnormalities, Radiation-Induced Clinical Trial

University Health Network, Toronto - Recruiting 18 years or older.
- Optical Coherence Tomography for Monitoring Late Oral Radiation Toxicity After Radiotherapy of Head and Neck Cancer Patients.

Cancer Clinical Trial

Policlinique M‚dicale Universitaire - Recruiting 18 years or older.
- Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment.

Locally Advanced Malignant Neoplasm, Oral Cancer, or Oropharyngea Clinical Trial using Neo-adjuvant Erbitux-based chemotherapy

Shanghai Jiao Tong University School of Medicine - Recruiting 18 years to 75 years.
- Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharyngeal Cancer.
Neo-adjuvant Erbitux-based chemotherapy

Prostate Cancer Clinical Trial using sildenafil 100mg

Seoul National University Bundang Hospital - Recruiting N/A or older.
- Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy.
sildenafil 100mg

Advanced Solid Tumors, Breast Cancer, Inflammatory Breast Cancer, Clinical Trial using CX-4945 oral formulation

Cylene Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma.
CX-4945 oral formulation

Metastatic Breast Cancer Clinical Trial using Icaritin

Chinese Academy of Medical Sciences - Recruiting 18 years to 65 years.
- A Phase I ,Single Center, Open-labeling, Single and Dose-escalating Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Oral Novel ERa36 Modifier Icaritin in Advanced Breast Patients.
Icaritin

Colorectal Cancer Clinical Trial using S-1, leucovorin, oxaliplatin

Peking University - Recruiting 20 years to 80 years.
- A Multicenter Feasibility Study With S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients With Untreated Metastatic Colorectal Cancer.
S-1, leucovorin, oxaliplatin

Pain, or Perioperative/Postoperative Complications Clinical Trial using pregabalin; placebo

National Cancer Institute (NCI) - Recruiting 18 years to 70 years.
- Effects of Oral Pregabalin Versus Placebo on Postoperative Pain and Morphine Consumption After Mastectomy.
pregabalin; placebo

Cancer of the Head and Neck, or Carcinoma, Adenoid Cystic Clinical Trial using Imatinib

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- Phase II Study of Imatinib (Glivec) Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Overexpressing KIT.
Imatinib